Automated And Closed Cell Therapy Processing Systems Market (2026 - 2033) Size, Share & Trends Analysis Report By Workflow (Separation, Expansion, Apheresis), By Type (Stem Cell Therapy), By Scale (Commercial Scale), By Region, And Segment Forecasts

Automated And Closed Cell Therapy Processing Systems Market Summary

The global automated and closed cell therapy processing systems market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.9 billion in 2026 to USD 7.4 billion by 2033, at a CAGR of 20.7% from 2026 to 2033. The market in North America dominated with a revenue share of 50.1% in 2025. The growing popularity of regenerative medicine & cell therapies, coupled with a range of benefits offered by automation technologies for developing these therapies, is expected to propel market growth.

In addition, the growing integration of software technologies and advanced therapy development processes is expected to drive market growth. Rising investments by bio manufacturers for developing cellular therapy products through rounds of series funding are anticipated to offer lucrative growth opportunities. Moreover, the increasing demand for scalable, safe, and contamination-free cell therapy manufacturing solutions, highlighted by innovations such as animal origin-free formulations, is driving the market’s growth. 

Growing Cell & Gene Therapy Pipeline Driving Manufacturing Demand

The expanding pipeline of cell and gene therapies, including CAR-T, NK, TCR-based, and emerging allogeneic modalities, is significantly increasing the need for scalable, high-throughput manufacturing systems. As more programs advance into clinical development, developers are experiencing rising pressure to enhance production capacity while maintaining strict quality and regulatory standards. This growth is also accompanied by an increasing number of autologous therapies, each requiring individualized processing, which further amplifies the strain on manual and semi-automated workflows.

With multiple late-stage cell therapy candidates moving closer to commercialization, manufacturers are prioritizing automated and closed systems to support larger batch volumes, greater operational efficiency, and stronger contamination control. Traditional manual processes are proving insufficient for meeting accelerated timelines, reproducibility expectations, and the higher throughput required as the market expands. Automated platforms that integrate cell isolation, activation, expansion, and formulation steps are becoming essential for reducing cycle times and ensuring consistent product quality.

In addition, the shift toward allogeneic, “off-the-shelf” cell therapies is reshaping production strategies and driving demand for systems that can support true industrial-scale manufacturing. These therapies rely on repeatable, high-yield processes that automated and closed platforms are better equipped to deliver. Collectively, the broadening therapeutic pipeline is prompting companies to invest heavily in next-generation manufacturing technologies to ensure scalability, efficiency, and sustained competitiveness in a rapidly evolving market.

CDMO Expansion Driving Turnkey Automation Demand

The growth of CDMOs and CROs, driven by rising outsourcing of cell therapy development and manufacturing, is creating strong demand for turnkey automated systems. As developers prioritize speed-to-market and flexible capacity, service providers are expanding their infrastructure and seeking platforms that support standardized, reproducible, and GMP-compliant production. Automated and closed systems enable CDMOs to manage diverse client portfolios, minimize operator dependency, and deliver consistent product quality across multiple therapy programs.

Simultaneously, increasing global investment in biomanufacturing facilities is accelerating the adoption of integrated, ready-to-deploy automation solutions. Companies building new sites or upgrading existing ones are prioritizing systems that reduce setup time, enhance scalability, and streamline validation processes. Turnkey automated platforms allow faster facility ramp-up, lower operational risk, and improved cost efficiency, making them a central component of modern cell therapy manufacturing strategies.

Market Concentration & Characteristics

Advancements in robotics, closed-loop control, AI-based monitoring, and modular single-use technologies are driving a high degree of innovation in the automated and closed cell therapy processing systems industry. The strong expansion of cell and gene therapy pipelines further accelerates demand for next-generation platforms that enhance scalability, reduce contamination risk, and ensure consistent, GMP-compliant production from development through commercial stages.

The level of M&A activities in the automated and closed cell therapy processing systems industry is medium, driven by strategic consolidation among technology providers, bioprocessing equipment manufacturers, and cell therapy-focused automation companies. Larger players are acquiring specialized platform developers to strengthen end-to-end manufacturing capabilities, expand product portfolios, and accelerate integration of robotics, software, and single-use technologies. For instance, in October 2025, NLS Pharmaceutics and Kadimastem entered into a definitive merger agreement and partnered with TargetGene to advance next-generation gene-edited cell therapies, exemplifying targeted, capability-driven consolidation in the market. While activity is steady, it remains focused on strategic acquisitions rather than large-scale consolidations, reflecting a still-maturing but rapidly evolving market.

Regulations have a high impact on the market, as cell and gene therapy manufacturing requires strict adherence to GMP, aseptic processing standards, and data integrity requirements. Regulatory agencies are increasingly emphasizing process standardization, closed-system operations, electronic batch records, and robust traceability, prompting manufacturers to adopt automated platforms that minimize manual intervention and ensure reproducible quality. Evolving guidelines for advanced therapies (ATMPs) continue to drive investment in compliant, scalable, and validated automated systems, which streamline approvals and reduce compliance risk.

The product expansion in the automated and closed cell therapy processing systems industry is high, supported by continuous innovation in integrated bioreactors, closed modular work cells, automated fill-finish units, and advanced software for analytics and monitoring. Manufacturers are expanding their portfolios to offer comprehensive, GMP-compliant solutions that enhance scalability, minimize labor dependency, and support a range of cell therapy modalities. Growing clinical and commercial demand further accelerates rapid product line diversification.

Regional expansion is moderate, driven by growing investments in cell therapy manufacturing hubs across North America, Europe, and the Asia Pacific region. Companies are establishing new facilities, forming partnerships, and setting up service centers to meet the growing demand for automated, closed-loop processing solutions. However, expansion remains concentrated in mature biomanufacturing regions, moderating the overall pace of global penetration.

Workflow Insights

The separation segment dominated the market, accounting for 31.72% share in 2025, and is expected to grow at the fastest CAGR of 21.91% over the forecast period. The segment’s growth is attributed to the need for enhanced efficiency, scalability, and cost reduction in cell therapy manufacturing, which is achieved through the automation of critical processes, such as cell expansion and separation. For instance, in June 2025, Xcell Biosciences announced a joint research collaboration with Thermo Fisher Scientific to advance next-generation cell therapies. The partnership focuses on automating and optimizing separation workflows, enhancing reproducibility, scalability, and GMP-compliant manufacturing for advanced cell therapy production.

The expansion segment is expected to grow significantly over the forecast period. The segment is driven by the increasing demand for scalable, efficient, and automated manufacturing solutions to improve the production and potency of cell and gene therapies, particularly for complex treatments such as solid tumors. For instance, in January 2024, Thermo Fisher Scientific launched Gibco CTS Cellmation Software, an off-the-shelf validated solution, designed to automate cell therapy manufacturing workflows. The software streamlines expansion and upstream processes, reducing manual interventions and contamination risk while enabling scalable, GMP-compliant, and efficient production across clinical and commercial stages.

Type Insights

The non stem cell therapy segment accounted for the largest market revenue share in 2025 and is expected to grow at the fastest CAGR over the forecast period. The increasing adoption of advanced gene-editing technologies for the precise treatment of diseases such as cancer, diabetes, and blood disorders drives the need for efficient, scalable, and safe cell therapy processing systems. For instance, in May 2025, CellFE and Made Scientific announced a strategic collaboration to advance non-viral gene editing for T-cell therapies. The partnership focuses on the non-stem cell therapy segment, enhancing upstream gene-editing workflows and enabling scalable, automated, and GMP-compliant manufacturing of engineered T-cell immunotherapies.

The stem cell therapy segment is expected to grow notably over the forecast period. The segment’s growth is attributed to the growing demand for scalable and efficient automation solutions to enhance the manufacturing, accessibility, and quality of stem cell therapies. For instance, in February 2025, Cellistic launched Allo Chassis, ready-to-use, immune-cloaked iPSC cell lines designed to streamline upstream cell therapy development. The product enables standardized, cGMP-compliant starting material, supporting scalable, automated, and closed-system manufacturing of allogeneic cell therapies while reducing time, cost, and complexity in the production pipeline.

Scale Insights

The pre-commercial/ R&D scale segment accounted for the largest market revenue share in 2025 and is expected to grow at a considerable CAGR over the forecast period. This growth is attributed to the need for automated, scalable quality control solutions to streamline manufacturing processes and overcome bottlenecks in pre-commercial and R&D stages of cell therapy development. For instance, in April 2024, Multiply Labs partnered with GenScript Biotech to automate the cell isolation and enrichment phase of cell therapy manufacturing. The collaboration focuses on R&D‑scale production, enhancing throughput, reproducibility, and process efficiency in early-stage and pre-commercial workflows, while laying the foundation for future scale-up to commercial manufacturing. 

The commercial scale segment is expected to experience significant growth over the forecast period. The need for scalable, efficient, and high-quality manufacturing solutions to support large-scale production of cell therapies for commercial applications is driving the segment’s growth. For instance, in April 2025, Cellares’s Cell Shuttle received FDA Advanced Manufacturing Technology (AMT) designation, recognizing its capability for automated, commercial-scale cell therapy manufacturing. The platform enables closed, high-throughput, GMP-compliant production, supporting the transition from clinical development to large-scale commercial supply of advanced cell and gene therapies.

Regional Insights

The North America automated and closed cell therapy processing systems industry held the largest share of 50.09% in 2025, owing to the increasing demand for integrated solutions that streamline the storage, transportation, and processing of cell and gene therapies, enhancing the efficiency of clinical trials and commercialization efforts. For instance, in June 2025, Cellular Origins announced a collaboration with Thermo Fisher Scientific to implement fully automated, robotic manufacturing of cell and gene therapies. The partnership utilizes closed-system, high-throughput platforms to facilitate scalable, GMP-compliant, and contamination-free production, thereby supporting the broader adoption of advanced cell therapy processing technologies.

U.S. Automated and Closed Cell Therapy Processing Systems Market Trends

The U.S. automated and closed cell therapy processing systems industry held a dominant position in 2025 and is expected to grow at the fastest CAGR over the forecast period due to the growing adoption of advanced robotics to streamline manufacturing processes, reduce labor costs, and enhance scalability and efficiency in cell therapy production. For instance, in September 2024, Multiply Labs announced a collaboration with Legend Biotech to automate cell therapy manufacturing using advanced robotic systems. This partnership was expected to evaluate Multiply Labs' robotic technology, which can seamlessly integrate with existing cell therapy processes, potentially reducing labor costs and improving manufacturing throughput.

Europe Automated and Closed Cell Therapy Processing Systems Market Trends

The automated and closed cell therapy processing systems industry in Europe is witnessing increasing demand for scalable, efficient, and automated solutions to enhance the production of high-quality cell therapies with minimal manual intervention. For instance, in October 2023, Bayer opened its first cell therapy manufacturing facility in the U.S., designed with flexible, modular spaces for cell culture, viral transduction, and automated filling of cell therapies. The facility leverages automated and closed processing systems to ensure scalable, GMP-compliant, and contamination-free production, supporting the advancement and commercial availability of regenerative medicines.

The UK automated and closed cell therapy processing systems industry is expected to grow at a significant rate over the forecast period due to increasing adoption of advanced manufacturing technologies, a strong pipeline of cell and gene therapies, and supportive government initiatives for biotech innovation. Rising investments in biomanufacturing facilities, coupled with the need for scalable, GMP-compliant production, are further driving demand for automated and closed processing platforms across clinical and commercial stages.

The automated and closed cell therapy processing systems industry in Germany is anticipated to experience robust growth from 2026 to 2033, driven by increasing investments in advanced biomanufacturing infrastructure, a growing pipeline of cell and gene therapies, and rising adoption of automation to ensure GMP-compliant, scalable, and contamination-free production. Supportive regulatory frameworks and collaborations between technology providers and biopharma companies are further accelerating market expansion.

Asia Pacific Automated and Closed Cell Therapy Processing Systems Market Trends

The automated and closed cell therapy processing systems industry in the Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period. This growth is attributed to the increasing investment in automation, which enhances efficiency, scalability, and precision in manufacturing advanced cell and gene therapies, thereby meeting the rising demand for high-quality treatments. For instance, in October 2025, IASO Bio partnered with Korea’s GC Cell to bring CAR‑T therapy to the Korean market. The collaboration is expected to leverage automated and closed cell therapy processing systems to enable scalable, GMP-compliant, and contamination-free manufacturing, supporting broader adoption of advanced cell and gene therapies in the region.

The China automated and closed cell therapy processing systems industry is expected to grow rapidly in the coming years due to the adoption of integrated, full-process automation technologies that enhance production efficiency, data monitoring, and support clinical trials and R&D in cell therapy development. For instance, in May 2025, Cellares and Mitsui Fudosan established a next-generation Smart Factory in Japan for commercial-scale cell therapy manufacturing. The facility utilizes automated and closed systems to produce CAR-T and other cell therapies, enabling scalable, GMP-compliant, and contamination-free production while supporting the broader adoption of advanced cell therapy processing technologies in the region.

The automated and closed cell therapy processing systems industry in Japan held a substantial market share in 2024, owing to the integration of robotics and pharmaceutical technologies to streamline production, improve manufacturing quality, and facilitate cost-effective technology transfer, supporting research institutions and startups in cell therapy development. For instance, in October 2025, Cell Therapies Pty Ltd. and Teijin Limited signed a Memorandum of Understanding (MoU) to expand access to advanced cell and gene therapies across Japan and the Asia‑Pacific region. The collaboration aims to accelerate the adoption of automated and closed cell therapy processing systems, enabling scalable, GMP-compliant, and contamination-free manufacturing in the region.

Middle East and Africa Automated and Closed Cell Therapy Processing Systems Market Trends

The automated and closed cell therapy processing systems industry in the Middle East and Africa is poised for growth, driven by increasing investments in biomanufacturing, rising adoption of advanced cell therapy technologies, and expanding healthcare infrastructure to support scalable, GMP-compliant, and contamination-free production.

The Kuwait automated and closed cell therapy processing systems industry is anticipated to witness growth over the forecast period, driven by increasing investments in advanced biomanufacturing facilities, the rising adoption of automated and closed processing technologies, and supportive government initiatives that promote cell and gene therapy development.

Key Automated and Closed Cell Therapy Processing Systems Company Insights

The market is highly competitive, dominated by a mix of established bioprocessing equipment manufacturers and specialized automation technology providers. Leading companies such as Miltenyi Biotec, Sartorius Stedim Biotech, Thermo Fisher Scientific, Lonza, and Danaher hold significant market shares, leveraging extensive product portfolios, global distribution networks, and strategic partnerships. Continuous R&D and product innovation allow these players to maintain a strong competitive position in a rapidly evolving market.

Mid-sized and emerging players, including WuXi AppTec, Berkeley Lights, Advanced Instruments, and Creative Biolabs, are gaining traction by offering niche solutions such as modular workcells, closed-system bioreactors, and AI-enabled process monitoring. These companies are forming collaborations with biopharma firms and CDMOs, benefiting from growing demand for scalable, GMP-compliant automated platforms. While their current market share is smaller, innovation-driven differentiation positions them for strong growth in the coming years.

Geographically, North America leads the market, driven by early adoption of advanced manufacturing technologies, the presence of major players, and robust investments in biomanufacturing infrastructure. Europe follows, with Germany, the UK, and France contributing significantly due to supportive regulatory frameworks, government initiatives, and thriving biotech ecosystems. The Middle East and Asia-Pacific regions are witnessing gradual market penetration, fueled by rising healthcare investments, expanding clinical trials, and the establishment of regional CDMOs adopting automated systems.

Overall, market share is distributed between large, established companies that generate high revenues from global operations and emerging innovators that gain relevance through specialized technologies. Strategic mergers, acquisitions, and partnerships are reshaping the competitive landscape, enabling key players to expand portfolios, enhance capabilities, and meet the growing needs of cell and gene therapy manufacturers across clinical and commercial stages. Innovation and consolidation trends are expected to further influence market shares over the forecast period.

Recent Developments

• In March 2025, Limula launched LimONE, an automated, closed, single-use system designed to standardize and scale cell therapy manufacturing. The platform targets CAR‑T and gene-edited cell therapies, reducing manual intervention while ensuring GMP-compliant, high-throughput production.

• In May 2024, ProPharma and PBL launched the Cell Factory Box, an innovative automated platform designed to streamline cell and gene therapy manufacturing. The system enables closed, scalable, and GMP-compliant production, enhancing process efficiency and reducing contamination risks.

Automated And Closed Cell Therapy Processing Systems Market Report Scope

Global Automated and Closed Cell Therapy Processing Systems Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)

  • Separation

  • Expansion

  • Apheresis

  • Fill- Finish

  • Cryopreservation

  • Others

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Stem Cell Therapy

  • Non Stem Cell Therapy

• Scale Outlook (Revenue, USD Million, 2021 - 2033)

  • Pre-Commercial/ R&D Scale

  • Commercial Scale

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait